- -

20

: Simvacor 20. ?  »
|
-

PER OS

Film Coated Tablets

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvacor is indicated to: Reduce the risk of total mortality by reducing coronary death Reduce the risk of non-fatal myocardial infarction Reduce the risk for undergoing myocardial revascularization procedures.Reduce the risk of stroke and transient ischemic attacks (TIA).Hyperlipidemia: Simvacor is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvacor therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios.Homozygous familial hypercholesterolemia: Simvacor is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvacor is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).

121 26 30128 00

Trima Israel Pharmaceutical Products Maabarot Ltd, Israel

06/2011 - 06/2021

.
, .
.
/
Simvastatin 20 MG
Blister pvc/aluminium 100 x TABLETS 24
Blister pvc/aluminium 5 x TABLETS 24
Blister pvc/aluminium 7 x TABLETS 24
Blister pvc/aluminium 10 x TABLETS 24
Blister pvc/aluminium 15 x TABLETS 24
Blister pvc/aluminium 20 x TABLETS 24
Blister pvc/aluminium 25 x TABLETS 24
Blister pvc/aluminium 30 x TABLETS 24

*

*

 

.

, .
:  »
 
" !
 
320